Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial.
Saved in:
| Title: | Mavacamten in Obstructive Hypertrophic Cardiomyopathy Patients Referred for Septal Reduction: Health Status Analysis Through Week 56 in VALOR-HCM Trial. |
|---|---|
| Authors: | Desai, Milind Y.1,2,3 (AUTHOR) desaim2@ccf.org, Owens, Anjali4 (AUTHOR), Wolski, Kathy2,3 (AUTHOR), Geske, Jeffrey B.5 (AUTHOR), Saberi, Sara6 (AUTHOR), Wang, Andrew7 (AUTHOR), Sherrid, Mark8 (AUTHOR), Cremer, Paul C.1,2,3 (AUTHOR), Lakdawala, Neal K.9 (AUTHOR), Tower-Rader, Albree10 (AUTHOR), Fermin, David11 (AUTHOR), Naidu, Srihari S.12 (AUTHOR), Smedira, Nicholas G.1,13 (AUTHOR), Schaff, Hartzell14 (AUTHOR), McErlean, Ellen2,3 (AUTHOR), Sewell, Christina2,3 (AUTHOR), Zhong, Yue15 (AUTHOR), Wyrwich, Kathleen W.1,15 (AUTHOR), Lampl, Kathy L.15 (AUTHOR), Sehnert, Amy J.15 (AUTHOR) |
| Source: | Journal of the American College of Cardiology (JACC). Sep2024, Vol. 84 Issue 11, p1041-1045. 5p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
